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Uracil DNA glycosylase (UNG) functions as a DNA repair or proofreading enzyme. The UNG gene is present in nearly all
prokaryotes and eukaryotes screened to date and is found in herpesviruses and poxviruses. Prior studies showed that viral
UNG is essential for poxvirus replication. Although viral UNG is not required for herpesvirus replication, cellular UNG was
thought to be essential for virus replication. To study the role of UNG in herpesvirus replication, we first showed that
varicella-zoster virus (VZV) ORF59 encodes a functional UNG. We then constructed a VZV mutant with a deletion in the UNG
gene and showed that the mutant was unimpaired for replication in vitro. Because cultured cells express their own
endogenous UNG, we next inserted a bacteriophage UNG inhibitor UGI gene into the VZV genome. Infection of cells with VZV
lacking viral UNG and expressing UGI completely abrogated detectable cellular UNG activity in vitro. Parental VZV, VZV
lacking viral UNG, and VZV expressing UGI all grew to similar titers in cell culture, indicating that VZV can replicate in vitro
in the absence of detectable viral or cellular UNG activity. © 1998 Academic Press
INTRODUCTION
DNA damage to mammalian cells and DNA viruses
must be repaired before replication to maintain the in-
tegrity of the genome. Uracil can be misincorporated into
DNA either during DNA replication or by spontaneous
deamination of cytosine. The presence of uracil in DNA
can result in mutations during replication or impaired
DNA synthesis with degradation of DNA (Mosbaugh and
Bennett, 1994). Uracil residues in the origin of replication
(oris) of herpes simplex virus (HSV) alter the interaction of
the origin binding protein with oris (Focher et al., 1992)
and may thereby interfere with viral replication.
Uracil DNA glycosylase (UNG) is a DNA repair enzyme
that removes uracil residues by cleaving the N-glycosylic
bond between the uracil base and the deoxyribose phos-
phate backbone of DNA, resulting in the release of uracil.
The resulting DNA containing an apyrimidinic site is
repaired by cellular enzymes. UNG is encoded by nearly
all eukaryotes and prokaryotes and also by herpesvi-
ruses and poxviruses. Deletion of UNG from HSV-1 has
no effect on virus growth in cultured cells, presumably
because the endogenous cellular UNG activity supplants
the viral enzyme (Mullaney et al., 1989; Pyles and Thomp-
son, 1994a). In contrast, replication of an HSV-1 UNG
mutant is severely impaired in nervous tissue compared
with wild-type virus (Pyles and Thompson, 1994a). This
difference in replication has been attributed to the lack of
detectable UNG activity in terminally differentiated neu-
rons, suggesting that UNG is required for replication in
the nervous system. Because in vitro studies of herpes-
viruses have all been conducted with cell lines that
express UNG, it has been difficult to assess the require-
ment of this enzyme for herpesvirus replication.
The Bacillus subtilis bacteriophage PBS2 has a ge-
nome that contains uracil residues in place of thymine
residues as a normal component of its DNA (Takahashi
and Marmur, 1963). To achieve this, PBS2 expresses a
UNG inhibitor (UGI) that prevents the removal of uracil
from the its genome by the bacterial UNG. The UGI gene
has been cloned, sequenced, and expressed in Esche-
richia coli (Wang and Mosbaugh, 1988, 1989). The UGI
protein irreversibly binds to and inactivates UNG ex-
pressed by prokaryotic and eukaryotic organisms (Kar-
ran et al., 1981; Moi et al., 1995), as well as by HSV-1 and
HSV-2 (Winters and Williams, 1990). Thus the UGI protein
can be used to study the replication of herpesviruses in
the absence of UNG.
Varicella-zoster virus (VZV) ORF59 encodes a protein
that is homologous to both HSV-1 and human UNG. The
VZV gene is predicted to encode a protein with 43%
identity and 59% similarity to HSV-1 UNG and with 32%
identity and 52% similarity to human UNG. Here we show
that the VZV ORF59 gene has UNG activity when ex-
pressed as a fusion protein in prokaryotic cells and that
deletion of a portion of ORF59 from VZV results in loss of
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viral UNG activity. To study the role of UNG in herpesvi-
rus replication, we inserted the UGI gene into VZV lack-
ing viral UNG and showed that the UNG inhibitor could
abolish cellular UNG activity. Surprisingly, VZV express-
ing the UGI gene was not impaired for growth in vitro.
Thus VZV can replicate in vitro in the absence of detect-
able cellular or viral UNG activity.
RESULTS
VZV ORF59 encodes the viral UNG
VZV ORF59 is homologous to mammalian and herpes-
virus UNG genes. To verify that ORF59 encodes UNG, a
fusion protein was constructed by expressing the entire
ORF59 gene fused to the gene encoding glutathione-S-
transferase (GST). Extracts were prepared from bacteria
containing the ORF59 fusion protein before and after
induction with isopropyl b-D-thiogalactoside (IPTG). UNG
activity was present in extracts from bacteria containing
the ORF59 fusion protein (pGEX-UNG.1 or 0.2) after IPTG
induction and in extracts from bacteria containing pGEX-
UNG.1 without induction (Table 1). No UNG activity was
present in bacteria containing the ORF59 deletion mutant
fusion protein (pGEX-UNG/D) or the GST protein alone
(pGEX-2T), indicating that UNG activity was due to the
full-length viral protein.
VZV UNG is not required for growth of the virus in
cell culture
VZV ORF59, which encodes the viral UNG, is located in
the VZV MstII A cosmid. Cosmid VZV MstII A-59D was
constructed with a deletion resulting in loss of codons
160–282 of ORF59 followed by a frameshift mutation
resulting in a change of the reading frame of the remain-
der of the gene. Cosmid MstII A-59D was transfected into
melanoma cells along with cosmids MstII B and NotI A
and plasmids NotI B and pCMV62. Six days after trans-
fection, the cells were treated with trypsin and passaged
in 75-cm2 flasks. Four or 5 days later (10–11 days after
transfection), cytopathic effects (CPE) typical for VZV
were noted. Transfection of the parental cosmid MstIIA,
in place of the mutated cosmid, also resulted in CPE
10–11 days after transfection. Two independent ORF59
deletion viruses, VZV ROka59DA and ROka59DB, derived
from two separate cosmid preparations were selected
for further study.
To verify that the VZV ORF59 mutants had the expected
genomic structures, virion DNAs from mutant and paren-
tal viruses were isolated and cut with BamHI, EcoRI, and
BssHII. Southern blot analysis of DNA cut with BamHI
(Fig. 1A) showed that the 10.6-kb BamHI B fragment
(open arrow) in VZV ROka is reduced to 10.2 kb (closed
arrow) in the ORF59 mutants, due to the loss of the DNA
segment in ORF59. The EcoRI site at nucleotide 100,441
is absent from ROka59D DNA; therefore, digestion of
ROka59D with EcoRI (Fig. 1B) results in a new band of
24.5 kb (closed arrow) and loss of the 16.6-kb EcoRI A
(open arrow) and 8.3-kb EcoRI G (open arrowhead) frag-
ments present in ROka. Digestion of ROka59D with
BssHII (Fig. 1C) cuts the 18.0-kb BssHII B fragment (open
arrow) of VZV DNA into two new bands of 13.2 and 4.4 kb
(closed arrows) due to the oligonucleotide, containing a
new BssHII site, inserted into the ROka59D genome.
UNG activity was assayed from lysates of uninfected
melanoma cells and cells infected with VZV ROka and
ROka59D. Lysates from cells infected with parental VZV
had higher nuclear UNG activity than lysates from unin-
FIG. 1. Southern blots of virion DNAs from VZV ORF59 mutants. Virion
DNA was digested with BamHI (A) or EcoRI (B) and probed with all four
radiolabeled cosmids or cut with BssHII (C) and probed with cosmid
MstIIA. Digestion of ROka59D with BamHI results in loss of the 10.6-kb
BamHI B fragment and a new band at 10.2 (A). Digestion of ROka59D
with EcoRI results in loss of 16.6- and 8.3-kb EcoRI A and G fragments
with a new band at 24.5 kb (B). Digestion of ROka59D with BssHII
results in loss of the 18-kb BssHII B and two new bands of 13.2 and 4.4
kb (C). Numbers indicate size of DNAs in kilobase pairs.
TABLE 1
UNG Activity in Lysates from Bacteria Expressing Fusion Proteins
Plasmid
UNG activity
(nmol/min/mg protein)a
Uninduced Induced
pGEX-UNG.1 0.038 .0.353
pGEX-UNG.2 0.000 0.112
pGEX-UNG/D 0.000 0.000
pGEX-2T 0.000 0.000
a Activities are means from at least two independent assays.
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fected cells, whereas lysates from cells infected with
either of the VZV ORF59 deletion mutants had an inter-
mediate level of nuclear UNG activity (Table 2).
To verify that each of the cell lysates was derived from
VZV-infected cells, another aliquot of each lysate was
immunoblotted using a murine monoclonal antibody to
VZV gE. Each of the VZV-infected cell lysates expressed
gE (Fig. 2).
Inability to express VZV ORF59 does not impair the
growth of virus in cell culture
The sizes of plaques produced in melanoma cells
infected with the two ORF59 deletion mutants (mean 6
SD, 0.70 6 0.10 and 0.63 6 0.12 mm) were similar to that
in cells infected with the parental virus (0.74 6 0.14 mm).
To determine whether there was a difference in growth of
the viruses, melanoma cells were infected with parental
or ORF59 mutant VZV, infected cells were harvested
daily, and virus was titrated on melanoma cells. VZV with
a deletion in ORF59 grew to similar titers as parental
virus (Fig. 3A).
Recent studies found that CMV unable to express viral
UNG is impaired for growth in human fibroblasts (Pri-
chard et al., 1996). To determine whether VZV UNG is
important for growth in fibroblasts, we performed growth
analyses in human embryonic lung fibroblasts. Unlike
the results observed with CMV, the titers of the parental
VZV and the UNG mutant were indistinguishable after
growth in human fibroblasts (Fig. 3B).
Expression of an UNG inhibitor fusion protein in E.
coli inhibits UNG activity in VZV-infected cells in vitro
Bacteriophage PBS2 contains an UNG inhibitor gene
(UGI) whose protein product inhibits both mammalian
and HSV UNG activity in extracts from virus-infected
cells. As an initial step in studying the role of UGI on VZV
replication, we constructed a fusion protein in which the
UGI protein was fused to GST. Because VZV replicates in
the nucleus, a second construct was made in which a
nuclear localization signal was fused to the carboxyl-
terminus of the UGI gene. Lysates were prepared from E.
TABLE 2
UNG Activity in Cytoplasmic and Nuclear Fractions
of VZV-Infected Cells
Virus
UNG activity
(nmol/min/mg protein)a
Cytoplasmic Nuclear
Uninfected 0.088 0.136
ROka 0.077 0.344
ROka59DA 0.060 0.281
ROka59DB 0.113 0.289
ROka14S 0.078 0.206
ROka14S/59D 0.080 0.365
ROka14S/UGI 0.000 0.019
ROka14S/UGI-NLS 0.000 0.042
ROka14S/59D/UGI 0.000 0.000
ROka14S/59D/UGI-NLS 0.000 0.000
a Activities are means from at least two independent assays.
FIG. 2. Immunoblot of lysates from cells infected with VZV mutants.
Each of the VZV-infected cells express 70- to 100-kDa proteins that
react with monoclonal antibody to VZV gE. Numbers indicate molecular
masses of proteins in kilodaltons.
FIG. 3. Growth curves of VZV ORF59 mutants in MeWo (A) and
human embryonic lung fibroblast (HELF) (B) cells. Cells were inocu-
lated with VZV-infected cells and 1–5 days later, the cells were treated
with trypsin, and the titer of virus was determined on MeWo cells. Day
0 indicates the titer of virus in the inoculum.
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coli that were uninduced or induced for 2.5 h with IPTG.
To verify that the UGI protein inhibits UNG activity in
virus-infected cells, serial dilutions of the bacterial ex-
tracts were added to lysates from VZV ROka-infected
cells that contain both cellular and viral UNG activity. The
addition of lysates from IPTG-induced bacteria express-
ing either UGI fusion protein strongly inhibited UNG
activity in VZV-infected cells (Fig. 4), whereas lysates
from uninduced bacteria inhibited UNG activity to a
lesser extent. In contrast, bacteria containing only the
GST protein without the UGI gene showed no inhibition.
Thus UGI expressed in E. coli inhibits both viral and
cellular UNG activity.
Expression of an UNG inhibitor gene by VZV
abolishes detectable UNG activity in virus-infected
cells in vitro
To analyze the ability of a herpesvirus to grow in the
absence of any UNG activity, we constructed VZV ex-
pressing UGI. Cosmid VZV NotI A-14S/UGI contains the
bacteriophage UNG inhibitor gene, driven by the human
CMV promoter, inserted into the dispensable VZV gC
gene (Cohen and Seidel, 1994). Because UNG is pre-
dominantly a nuclear protein, a second cosmid was
constructed, VZV NotI A-14S/UGI-NLS, which contains a
nuclear localization signal fused to the carboxyl-terminus
of the UNG inhibitor gene. Transfection of melanoma
cells with plasmids NotI B and pCMV62, cosmids MstII A
and MstII B, and either VZV NotI A-14S/UGI or VZV NotI
A-14S/UGI-NLS, resulted in CPE similar to those seen
with VZV generated from parental cosmids. Two viruses,
VZV ROka14S/UGI and ROka14S/UGI-NLS, were se-
lected for further study.
To produce VZV that has a deletion in the viral UNG
and expresses UGI, melanoma cells were transfected
with plasmids NotI B and pCMV62, cosmids MstII B and
MstII A-59D, and VZV NotI A-14S/UGI or NotI A-14S/UGI-
NLS. CPE typical of VZV were observed in the cells.
Viruses VZV ROka14S/59D/UGI and ROka14S/59D/UGI-
NLS were obtained.
Viral DNA was obtained from cells infected with VZV
expressing UGI and analyzed by Southern blotting.
Digestion of virion DNA with BamHI (Fig. 5A) showed
a 10.6-kb band (open arrow) from viruses with the
ORF59 gene intact and a 10.2-kb band (closed arrow)
from viruses with the ORF59 deletion due to the DNA
segment deleted from ORF59. In addition, the 8.1-kb
BamHI F fragment (open arrow) into which the UGI
gene was inserted was cut into two bands of 6.4 kb
(closed arrow) and 2.9 kb (not visible on this exposure)
due to the BamHI site present in the UGI gene. Diges-
tion of virion DNA with EcoRI (Fig. 5B) showed a band
of 24.5 kb (closed arrow) from viruses with the ORF59
deletion and bands of 16.6 kb (open arrow) and 8.3 kb
(open arrowhead) from viruses with the ORF59 gene
intact due to the loss of the EcoRI site at 100,441 that
is missing from the ORF59 deletion mutants. In addi-
tion, the 1.75-kb EcoRI N fragment (open arrow) is
slightly smaller in viral DNAs containing the UGI gene
(closed arrow) due to the EcoRI site present in UGI
(see below). Digestion of virion DNA with KpnI and PstI
FIG. 5. Southern blots of virion DNAs from VZV UGI insertion mu-
tants. Virion DNA was digested with BamHI (A) or EcoRI (B) and probed
with all four cosmids, cut with KpnI and PstI, and probed with a
fragment containing the ORF59 gene (C) or cut with EcoRI and probed
with the UGI gene (D). Digestion of VZV containing the UGI inhibitor
with BamHI (A) results in loss of the 8.1-kb BamHI F fragment with a
new band of 6.4 kb. Virion DNA from VZV with the ORF59 deletions
shows loss of a 10.6-kb band (described in the legend to Fig. 1).
Digestion of VZV containing the UGI inhibitor with EcoRI (B) results in
loss of the 1.75-kb EcoRI N fragment and a new band of 1.7 kb. Virion
DNA from VZV with the ORF59 deletions shows a new band of a 24.5-kb
band (described in the legend to Fig. 1). Digestion of VZV with the
0.4-kb deletion in ORF59 shows a band of 1.5 kb, compared with 1.9 kb
in VZV containing full-length ORF59 (C). Digestion of VZV containing the
UGI inhibitor with EcoRI followed by a UGI gene probe shows two
bands of 1.7 and 1.3 kb (D).
FIG. 4. UGI expressed in E. coli inhibits UNG activity in vitro. Serial
dilutions of extracts from uninduced or IPTG-induced E. coli expressing
UGI (pGEX-UGI) or UGI with a nuclear localization signal (pGEX-UGI-
NLS) were added to an extract of VZV ROka-infected MeWo cells, and
UNG activity was measured.
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followed by hybridization with a probe encompassing
ORF59 (Fig. 5C) showed a band of 1.9 kb from viruses
with a full-length ORF59 gene and a band of 1.5 kb
from viruses with the deletion in ORF59 due to the
0.4-kb deletion in ORF59. Digestion of virion DNAs
containing the UGI gene with EcoRI, followed by hy-
bridization with the UGI gene probe (Fig. 5D), shows
two bands of 1.7 and 1.3 kb due to the UGI gene
inserted into the EcoRI N fragment of VZV.
Nuclear and cytosolic fractions were obtained from
cells infected with VZV expressing the UGI gene and
assayed for UNG activity. Lysates from cells infected
with VZV with a deletion in ORF59 and containing the
UGI gene with or without a nuclear localization signal
had no detectable UNG activity (Table 2). Lysates from
cells infected with VZV with an intact ORF59 gene and
the UGI gene had no detectable cytosolic and minimal
nuclear UNG activity. The presence or absence of a
nuclear localization signal on UGI had little if any
effect on UNG expression. These results indicate that
VZV can replicate in cells despite the absence of
detectable UNG activity.
Immunoblots were performed using a murine mono-
clonal antibody to VZV gE to ensure that each of the
lysates contained VZV-infected cells. gE was detected
from each of the virus-infected cell lysates (Fig. 2).
To further verify that MeWo cells expressing UGI could
inhibit UNG activity, cytosolic or nuclear extracts were
prepared from cells infected with VZV expressing the
UGI gene and mixed with lysates from uninfected, VZV
ROka, or VZV ROka59D cells. The addition of extracts
from cells expressing UGI inhibited cellular UNG activity
(in uninfected or VZV ROka59D-infected cells) by .80%,
whereas UNG activity of VZV-infected cells (containing
both cellular and viral UNG) was inhibited by .40%
(Table 3). Both cytosolic and nuclear extracts contained
UGI activity.
Cellular and viral UNG are dispensable for growth of
VZV in cell culture
Cells infected with VZV expressing the UGI gene with
or without a nuclear localization signal had plaque sizes
(0.90 6 0.31 and 1.06 6 0.41 mm, respectively) that were
similar to those in cells infected with the parental virus
(0.94 6 0.09 mm). In addition, cells infected with VZV
containing the UGI gene with or without a nuclear local-
ization signal and a deletion in ORF59 had plaque sizes
(0.90 6 0.19 and 1.04 6 0.33 mm, respectively) that were
similar to those in cells infected with the parental virus
(0.94 6 0.09 mm).
The growth of VZV mutants expressing the UGI gene
was assayed on melanoma cells. VZV expressing the
UGI gene, in either the presence or absence of the
ORF59 gene, grew to titers comparable to those seen
with parental virus (Fig. 6).
DISCUSSION
We have shown that VZV encodes a functional UNG
and that the inability to express this protein does not
impair replication. In addition, expression of UGI in VZV
lacking viral UNG abrogates detectable cellular UNG
activity but does not impair viral replication in vitro.
Nearly all eukaryotic organisms express UNG (Mos-
baugh and Bennett, 1994). All eight human herpesviruses
encode UNG (Mullaney et al., 1989; Nicholas 1996; Pri-
chard et al., 1996; Russo et al., 1996; Winters and Wil-
liams, 1993). It was postulated that viral UNG activity is
needed to increase deoxyribonucleoside triphosphate
pools in herpesvirus-infected cells for efficient replica-
tion of viral DNA (Jamieson and Bjursell, 1976). A reduc-
tion in overall UNG activity might thereby inhibit viral
replication or result in an increase in the rate at which
mutations accumulate in the viral genome.
VZV with a deletion in UNG grew to similar titers in
vitro as parental virus. Similarly, HSV-1 unable to express
the viral UNG gene is not impaired for growth in cell
culture (Mullaney et al., 1989; Pyles and Thompson,
1994a). In contrast, Prichard et al. (1996) reported that
CMV with a deletion in the UNG gene had a delay in viral
FIG. 6. Growth curves of VZV containing UGI in MeWo cells. MeWo
cells were inoculated with VZV-infected cells, and 1–5 days later, virus
was titered as described in the legend to Fig. 3.
TABLE 3
Addition of Extracts from VZV-Infected Cells Containing UGI
Inhibitor to Other Infected Cells
Cell extract
infected with:
Percent inhibition of control
Cytosolic extract Nuclear extract
UGI/NLSa UGIb UGI/NLS UGI
Uninfected 100 100 99 82
ROka 68 57 65 42
ROka59DA 100 100 100 84
ROka59DB 100 100 100 92
a Cytosolic and nuclear extracts were prepared from cells infected
with ROka14S/59D/UGI-NLS.
b Cytosolic and nuclear extracts were prepared from cells infected
with ROka14S/59D/UGI.
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DNA synthesis and replication. They postulated that the
difference between the phenotypes of the CMV and
HSV-1 mutants may have been due to the cell types used
in the experiments. The CMV mutant was assayed in
human fibroblasts (Prichard et al., 1996), whereas the
HSV mutants were tested in continuous cell lines (Pyles
and Thompson, 1994a). Our observation that VZV unable
to express UNG was unimpaired for growth in either
human fibroblasts or in a continuous cell line indicates
that the cell type alone is not responsible for these
growth differences and that there must be other differ-
ences between the human alphaherpesviruses and cy-
tomegalovirus that contribute to the observed growth
phenotypes of the UNG mutant viruses.
Cells infected with VZV lacking viral UNG and express-
ing UGI had no detectable cellular UNG activity; how-
ever, viral replication was unimpaired in vitro. Because
viral UNG is dispensable for HSV replication (Mullaney et
al., 1989), it was postulated that the mammalian UNG,
located in the nucleus and mitochondria (Nagelhus et al.,
1995; Slupphaug et al., 1993), could substitute for the lack
of the herpesvirus enzyme (Ellison et al., 1996). The
ability of our VZV mutant to replicate in cells expressing
no detectable UNG activity suggests that this enzyme is
dispensable for growth of VZV in vitro. This conclusion
requires two clarifications. First, although we were un-
able to detect UNG activity in either cytoplasmic or nu-
clear extracts from cells infected with VZV lacking viral
UNG and expressing UGI, it is possible that UGI could be
sequestered from UNG in some compartment of the cell
and that only after the extracts are produced could the
inhibitor inactivate the sequestered enzyme. Second,
cells infected with VZV lacking viral UNG and expressing
UGI might produce very low levels of UNG activity that
are below the level of detection of our assay.
In contrast to the herpesviruses, viral UNG is essential
for replication of poxviruses (Ellison et al., 1996; Stuart et
al., 1993). This was thought to be due to the fact that
poxviruses replicate in the cytoplasm and therefore pox-
virus UNG mutants could not be complemented by nu-
clear or mitochondrial UNG activity. However, because
detectable cellular UNG activity is not required for repli-
cation of VZV in vitro, the essential nature of the poxvirus
UNG is probably due to a unique feature of the viral UNG
and not due to a lack of UNG activity in the cytoplasm.
The finding that UGI does not inhibit the vaccinia UNG
also supports this latter hypothesis (Ellison et al., 1996).
Although the HSV UNG is dispensable for growth in
cell culture, an HSV mutant lacking this gene shows an
increase in accumulation of mutations compared with
parental virus (Pyles and Thompson, 1994b) and is im-
paired for replication and reactivation from latency in the
murine nervous system (Pyles and Thompson, 1994b).
Because UNG is not present in adult neurons (Focher et
al., 1990; Verri et al., 1992), this implied that the HSV
enzyme might be required for growth in the nervous
system (Pyles and Thompson, 1994b). However, our VZV
mutant lacking viral UNG and expressing UGI grew in
cells lacking any detectable UNG activity and achieved
titers similar to those seen with parental virus in vitro.
Thus our results suggest that the impairment of the HSV
UNG mutant for replication in the central nervous system
might not be due to the lack of enzymatic activity of UNG.
Because mammalian UNG has been shown to have a
nonenzymatic activity (i.e., binding to DNA polymerase
alpha) (Lee and Sirover, 1989), this or another activity of
the protein may be important for the difference in repli-
cation and reactivation from the nervous system.
Herpesvirus UNG activity has been proposed as a
target for antiviral chemotherapy (Argnani et al., 1995).
Although UNG may have other nonenzymatic activities
that influence the growth of herpesviruses in the nervous
system, our finding that VZV can replicate in vitro in the
absence of detectable UNG activity suggests that inhi-
bition of its enzymatic activity per se may not be very
effective for antiviral therapy.
MATERIALS AND METHODS
Cells and virus
Human melanoma (MeWo) cells (a gift of C. Grose)
were used for propagating virus, transfections, and
growth studies of viral mutants. Human embryonic lung
fibroblasts (HELF) (a gift of P. Brunell) also were used for
growth studies of VZV mutants. Recombinant VZV was
derived from the attenuated Oka strain (provided by M.
Takahashi).
Cosmids and plasmids
VZV cosmids NotI A, MstII A, MstII B, and plasmid NotI
B contain the entire genome of the Oka strain of VZV (Fig.
7). ORF59 (VZV nucleotides 101,219–100,305) is predicted
to encode the viral UNG. To produce a cosmid with a
deletion in ORF59 of VZV, cosmid MstIIA was cut with
NheI, and the 9.7-kb fragment (VZV nucleotides 91,047–
100,740) was inserted into the NheI site of plasmid pLit-
mus38 (New England Biolabs, Beverly, MA) to produce
plasmid pLit-NheI. A double-stranded oligonucleotide,
TTAACCTAGGTGGCGCGCCTAGATAG, containing stop
codons in all three reading frames and AscI and AvrII
restriction sites was inserted into the AflII site of plasmid
pLit-NheI. A plasmid containing the oligonucleotide in-
serted in the correct orientation was cut with SalI (which
cuts at VZV nucleotide 100,370 and in the multiple clon-
ing site of pLitmus). The large 12.1-kb fragment was
ligated to itself, and two independent clones were se-
lected. Each clone was cut with NheI and AvrII, and the
large fragment containing the mutated VZV DNA was
inserted in place of the wild-type NheI fragment in cos-
mid VZV MstII A to create cosmids VZV MstII A-59DA and
MstII A-59DB. These cosmids have a deletion in ORF59
from VZV nucleotides 100,370–100,740.
To construct a VZV cosmid containing UGI, the UGI
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gene from the B. subtilis bacteriophage PBS2 (Wang and
Mosbaugh, 1989) was amplified using PCR with oligonu-
cleotides GGAGGAATTCCAACATGACAAATTTATCTGAC
and CGTTGGATCCTTATAACATTTTAATTTTATTTTCTCC. A
second construct, containing a nuclear localization sig-
nal at the carboxyl-terminus of UGI, was constructed by
PCR with oligonucleotides GGAGGAATTCCAACATGA-
CAAATTTATCTGAC and CGTTGGATCCTTAGACCTTTCG-
CTTCTTCTTTGGTAACATTTTAATTTTATTTTCTCCATT. The
nuclear localization signal PKKKRKV was derived from
the simian virus 40 (SV40) large T antigen (Kalderon et
al., 1984). The PCR products were digested with EcoRI
and BamHI and inserted into the corresponding sites of
a modified form of plasmid pCDNA3 (InVitrogen, Carls-
bad, CA). The latter plasmid has a new polylinker in
which the orientations of the EcoRI and BamHI sites
have been reversed relative to the location of the CMV
promoter that drives the insert. Plasmids pCDNA3-UGI
and pCDNA3-UGI-NLS (which has the SV40 nuclear lo-
calization signal) contain the UGI gene cloned into
pCDNA3. Two independent plasmids containing each
construct were cut with PvuII and NruI, and the 1.38-kb
fragment containing the UGI or UGI-NLS gene driven by
the human cytomegalovirus immediate–early promoter
and followed by the bovine growth hormone gene poly-
adenylation signal was cloned into the AscI site of cos-
mid VZV NotI A-14S (Cohen and Seidel, 1994). The re-
sulting cosmids VZV NotI A-14S/UGIA, NotI A-14S/UGIB,
NotI A-14S/UGI-NLSA, and NotI A-14S/UGI-NLSB contain
the UGI gene inserted into the VZV genome after the 15th
codon of the VZV ORF14 gene (which encodes glyco-
protein C).
Transfections
VZV cosmids were digested with NotI or Bsu36I to
linearize VZV insert DNA, extracted with phenol, and
precipitated. Then 1.5 mg each of VZV cosmids MstII B
and NotI A and plasmid pNotI B, 0.75 mg of cosmid MstII
A, 50 ng of pCMV62, and 2 mg of salmon sperm DNA
were used to transfect MeWo cells by the calcium phos-
phate procedure (Cohen and Seidel, 1993). Cosmid MstII
FIG. 7. Construction of VZV ORF59 deletion and UGI insertion mutants. The prototype VZV genome (Davison and Scott, 1986) is 124,884 bp in length
(line 1) and consists of terminal repeat (TR), unique long (UL), internal repeat (IR), and unique short (US) DNA domains (line 2). NotI (line 3) and MstII
(line 4) restriction fragments are used to generate recombinant VZV. The 39 end of the NotI A fragment (indicated in parentheses) terminates within
the R3 repeat region (before nucleotide 45,295). Cosmid MstII A-59D has a deletion in ORF59 resulting in loss of codons 160–282 (line 5). Cosmid
NotI A-14S (line 6) has a stop codon inserted in VZV ORF14 (gC). Cosmid NotI A-14S/UGI (line 7) has the UGI gene and cosmid NotI A-14S/UGI-NLS
(line 8) has the UGI gene with a nuclear localization signal inserted after the 15th codon of the VZV ORF14 gene.
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A-59D was used in place of MstII A to construct VZV
lacking viral UNG. Cosmids NotI A-14S/UGI or NotI
A-14S/UGI-NLS were substituted in place of NotI A to
generate VZV expressing the bacteriophage UGI. The
cells were treated with trypsin, seeded into 75-cm2 flasks
6 days after transfection, and monitored daily for CPE.
Southern blots
VZV DNA was purified from nucleocapsids as de-
scribed previously (Cohen and Seidel, 1993). Viral DNA
was cut with EcoRI, BamHI, BssHII, or KpnI and PstI and
fractionated on 0.8% agarose gels. After transfer of the
viral DNA to nylon membranes, the blot was probed with
[32P]dCTP-radiolabeled DNA derived from all four VZV
cosmids corresponding to the complete VZV genome,
VZV cosmid MstII A, the ORF59 gene, or the UGI gene.
Growth characteristics of recombinant VZV
Cells containing ;100 pfu of parental or mutant VZV
were used to infect MeWo or HELF cells. At 1–5 days
after infection, the cell monolayers were treated with
trypsin, and serial 10-fold dilutions were used to inocu-
late fresh MeWo cells. Plates were incubated at 32°C for
7 days before staining with crystal violet.
Generation of UNG VZV and inhibitor fusion proteins
The coding region of VZV ORF59 was amplified by PCR
using two primers. The first primer contained a BamHI
site followed by VZV nucleotides 101,219–101,200 (CATG-
GATCCATGGATGTGTCTGGGGAGCC), and the second
primer contained a BamHI site followed by VZV nucleo-
tides 100,302–100,322 (CATGGATCCTTATATAACACTCC-
AATCGAT). The amplified DNA was digested with BamHI
and inserted into plasmid pGEX-2T (Pharmacia, Piscat-
away, NJ), which contains a portion of the GST gene to
produce plasmid pGEX-UNG. Two independent clones,
pGEX-UNG.1 and pGEX-UNG.2, were selected. The cod-
ing region from the ORF59 deletion mutant was also
amplified by PCR and cloned into pGEX-2T to generate
pGEX-UNG/D.
The coding region of the bacteriophage UGI gene was
amplified by PCR using oligonucleotides GATCGGATC-
CAACATGACAAATTTATCTGACAT and CGTTGGATCCTT-
ATAACATTTTAATTTTATTTTCTCC, containing BamHI sites.
The amplified DNA was digested with BamHI and in-
serted into plasmid pGEX-2T to yield plasmid pGEX-UGI.
A second construct was made by PCR using oligonucle-
otides GATCGGATCCAACATGACAAATTTATCTGACAT and
CGTTGGATCCTTAGACCTTTCGCTTCTTCTTTGGTAACA-
TTTTAATTTTATTTTCTCCATT. The amplified DNA was di-
gested with BamHI and inserted into pGEX-2T to yield
plasmid pGEX-UGI-NLS. Plasmids pGEX-UNG, pGEX-
UNG/D, pGEX-UGI, and pGEX-UGI-NLS were grown in E.
coli strain CJ236 (dut2, ung2). To induce expression of
the fusion proteins, bacteria were inoculated into 2XYT
medium with 2% glucose and ampicillin and grown to an
A600 of 0.4, and IPTG was added for 2 h.
UNG assays
Uninfected or infected MeWo cells (48 h after infection)
were scraped from flasks, washed in phosphate-buffered
saline, pelleted, resuspended in 5 ml of buffer (50 mM
Tris–HCl, pH 8.0, 5 mM MgCl2, 100 mM NaCl, 0.5%
Nonidet P-40), and allowed to swell on ice for 10 min. The
cells were lysed in a dounce homogenizer (10 strokes).
Nuclear and cytosolic extracts were separated by cen-
trifugation (800 g) at 4°C for 5 min. Nuclei were resus-
pended in extraction buffer (10 mM Tris–HCl, pH 7.5, 250
mM NaCl, 1 mM DTT, and 1 mM EDTA) and assayed for
UNG activity. Bacterial cell pellets were resuspended in
extraction buffer, lysed by sonication (Branson Sonifier
model 350; microprobe power setting 5 for 15-sec pulses
for 3 min), and centrifuged at 9000 g for 30 min, and the
supernatant was assayed for enzymatic activity.
UNG assays were performed at 37°C in 0.2-ml reac-
tion mixtures containing bacterial or cellular samples in
50 mM Tris–HCl, pH 7.5, 2 mM DTT, 10 mM EDTA, 0.01%
(w/v) bovine serum albumin, and 4 mg of [3H]uracil calf
thymus DNA (6000 cpm/mg), prepared by nick translation
using [3H]dUTP (Rigby et al., 1977). The reactions were
terminated by placing the samples on ice and adding 25
ml of calf thymus DNA (1 mg/ml) and 25 ml of ice-cold
50% (w/v) trichloroacetic acid. After 20 min on ice, the
samples were centrifuged (1100 g for 5 min), and 0.2 ml
of supernatant from each reaction was added to 4 ml of
Beckman Ready Solve scintillation cocktail and neutral-
ized by the addition of 75 ml of 1.2 M KOH. The amount of
radioactivity was measured in a Beckman LS-8100 scin-
tillation spectrophotometer. One unit of UNG activity was
defined as the amount of enzyme that released 1 nmol of
[3H]uracil/min at 37°C (Winters and Williams, 1990).
As a control, UNG assays also were performed using
the same reaction conditions described above with bac-
teria extracts expressing viral UNG; however, [3H]thymi-
dine calf thymus DNA was substituted in place of [3H]u-
racil calf thymus DNA. Although the [3H]uracil DNA was
completely degraded after 30 min, the [3H]thymidine
DNA was not degraded after 5 h. Thus the UNG assay
was specific for degradation of uracil and not thymidine.
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